Views | |
---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 125 |
November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | |
---|---|---|---|---|---|---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 3 | 0 | 1 | 8 | 3 | 0 | 3 |
Views | |
---|---|
2021_Frost_etal.pdf | 185 |